Market Newsdesk

Selected instruments are tradable from 5:25pm until 5:00am JST

The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough Therapy and EMA PRIME designations, and recent positive feedback from the FDA Neurology Division.

UK Credit Card Payment Rates Drop and Card Balances Rise as Summer Spending Puts Pressure on Consumers

FICO UK Credit Card Market Report for June 2026 identifies the need for increased vigilance on late payments by risk teams

LONDON–(BUSINESS WIRE)–
As summer spending rose in June, credit card data analysis for June 2026 by global analytics software leader FICO (NYSE: FICO) underlines the financial pressures facing UK households. Falling payments contributed to an annual increase in accounts with one, two and three missed payments. And with average balances across all three delinquent categories rising month-on-month, risk teams will need to maintain heightened monitoring for signs of pressure on affordability.

Highlights

• Average spend increased by 5.6% month-on-month, to £835.

• The average active balance increased by 1.4% month-on-month, reaching a new record high of £1,975. It is also 4.7% higher than June 2025.

• The percentage of balance paid decreased by 2.4% month-on-month to 33.3%, and remaining 4.4% lower year-on-year.

• The percentage of customers missing one payment increased 7.7% year-on-year, with the average balance on accounts with one missed payment 4.1% higher

• There was a 5.5% increase, month-on-month, in customers missing two payments and 9.1% year-on-year, with the average balance increasing 2.2% year-on-year

• For customers missing three payments, there was a significant 14.3% year-on-year increase, with the average balance 1.9% higher than the same month in 2025.

• Average credit limits increased by 0.2% month-on-month to £5,985, remaining 2.0% higher year-on-year.

FICO Comment:

June 2026 continued to present a mixed picture for consumer affordability. An increase in spending could, potentially, be seen as a good sign of economic confidence, however, the increase in spending was not matched by the percentage of overall balance paid, which fell on the previous month and year, reversing the previous recovery and continuing its persistent downwards trend. And with an increase in late payments across one, two and three months, a record-high average active balance will be of concern to risk teams.

Payment rates remain at historically low levels, close to the pre-pandemic average of 30%. With rising spending and payments to balance, the average active balance has maintained record highs, a trend that characterised the market throughout 2025 and into 2026.

In terms of missed payments, June saw a mixed picture across delinquency categories, with month-on-month improvements in one and three-cycle accounts offset by an increase at two cycles. However, all three delinquency categories remain higher year-on-year, continuing the concerning trend that emerged in the second half of 2025 and has persisted throughout 2026.

June credit card data indicates that underlying affordability pressures remain significant. Risk teams should maintain heightened monitoring of delinquency progression through the cycle buckets and ensure pre-delinquency intervention strategies remain calibrated to address the elevated balance levels now characteristic of customers in financial difficulty.

Key Trend Indicators – UK Cards June 2026

Metric	Amount	Month-on-Month Change	Year-on- Year Change
Average UK Credit Card Spend	£835	+5.6%	+0.9%
Average Card Balance	£1,975	+1.4%	+4.7%
Percentage of Payments to Balance	33.3%	-2.4%	-4.4%
Accounts with One Missed Payment	1.4%	-7.7%	+7.7%
Accounts with Two Missed Payments	0.3%	+5.5%	+9.1%
Accounts with Three Missed Payments	0.2%	-13.9%	+14.3%
Average Credit Limit	£5,985	+0.2%	+2.0%
Average Overlimit Spend	£95	-4.1%	+3.3%
Cash Sales as a % of Total Sales	0.8%	+0.5%	-4.4%
Source: FICO

These card performance figures are part of the data shared with subscribers of the FICO® Benchmark Reporting Service. The data sample comes from client reports generated by the FICO^® TRIAD^® Customer Manager solution in use by some 80% of UK card issuers. For more information on these trends, contact FICO.

About FICO

FICO (NYSE: FICO) powers decisions that help people and businesses around the world prosper. Founded in 1956, the company is a pioneer in the use of predictive analytics and data science to improve operational decisions. FICO holds more than 200 US and foreign patents on technologies that increase profitability, customer satisfaction and growth for businesses in financial services, insurance, telecommunications, health care, retail and many other industries. Using FICO solutions, businesses in more than 80 countries do everything from protecting 4 billion payment cards from fraud, to improving financial inclusion, to increasing supply chain resiliency. The FICO® Score, used by 90% of top US lenders, is the standard measure of consumer credit risk in the US and has been made available in over 40 other countries, improving risk management, credit access and transparency. Learn more at www.fico.com.

FICO and TRIAD are registered trademarks of Fair Isaac Corporation in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260824172828/en/

For further press information please contact:

FICO UK PR Team

Wendy Harrison/Matthew Enderby

[email protected]

0208 977 9132

KEYWORDS: Europe Ireland United Kingdom

INDUSTRY KEYWORDS: Data Analytics Finance Banking Data Management Professional Services Technology Fintech Business

MEDIA:

Logo

Paysafe Launches Video Gaming Arena to Connect Publishers with Millions of Gamers

New platform combines game discovery, rewards, exclusive content to help developers grow their audiences and deepen player engagement

LONDON–(BUSINESS WIRE)–Paysafe (NYSE: PSFE), a leading payments platform, today announced the launch of a gaming arena designed to connect gamers, developers and publishers through a destination focused on game discovery, rewards and community.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824546174/en/

Building on PaysafeCard‘s longstanding position in gaming, the arena enables players to discover new titles, access exclusive content and promotions, engage with creators and unlock rewards. Via PaysafeWallet, gamers can experience seamless purchasing, funding and checkout experiences. For developers and publishers, the arena provides a new customer acquisition channel with access to Paysafe’s global gaming audience of approximately 19 million customers.

The initiative reflects Paysafe’s vision of expanding its role in gaming beyond payments, creating new opportunities for players and publishers to connect and grow.

The arena will offer:

• Personalized game discovery and recommendations

• Esports events

• Rewards experiences

• Gift cards and digital gaming vouchers

• Exclusive game access, promotions and events

• Creator- and influencer-led campaigns

• Integrated payment experiences

• Audience insights and targeting tools

• End-to-end solutions for publishers including Merchant of Record (MOR) and Storefront

For publishers and developers, the arena addresses one of the industry’s biggest challenges: discoverability. The platform enables developers to showcase games, run campaigns, distribute promotions and gain insights into customer engagement and performance.

“We’re creating a bridge between gamers and game publishers,” said Bob Legters, Chief Product Officer at Paysafe. “The gaming arena combines discovery, community engagement and the seamless purchasing experiences enabled by PaysafeCard and PaysafeWallet to help players find new experiences and help publishers grow their reach.”

As the arena evolves, developers and publishers interested in participating in the next phase of the initiative can express interest by contacting Paysafe.

About Paysafe

Paysafe is a global payments platform powering the experience economy, with a strong focus on the iGaming, video gaming, e-commerce, online trading, retail, travel and hospitality sectors. With 30 years of expertise in payment technology, Paysafe helps businesses and consumers lift every experience through seamless, secure payment solutions, including card payments, digital wallets such as Skrill, eCash solutions like PaysafeCard, and a suite of local payment methods. With approximately 2,800 employees across 12 countries and annualized transactional volume of $167 billion in 2025, Paysafe connects people and businesses worldwide through innovative digital payment experiences. Further information is available at www.paysafe.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260824546174/en/

For further information about Paysafe, please contact:

The Paysafe Press Office via [email protected]

KEYWORDS: North America United States Ireland United Kingdom Europe

INDUSTRY KEYWORDS: Software eSports Sports Entertainment Payments Electronic Commerce Apps/Applications Technology Digital Cash Management/Digital Assets General Entertainment Other Entertainment Electronic Games Other Technology

MEDIA:

Logo

European Commission Approves DAYBU^® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

SAN DIEGO–(BUSINESS WIRE)–
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU).

“The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment.”

The DAYBU marketing authorization in the EU is primarily based on results from the Phase 3 LAVENDER™ study, which demonstrated statistically significant and clinically meaningful improvements in core features of Rett syndrome, as measured by the Rett Syndrome Behaviour Questionnaire (RSBQ) and Clinical Global Impression-Improvement (CGI-I) scale co-primary endpoints.

“Rett syndrome places a profound burden on individuals, families, and caregivers, yet treatment options have remained extremely limited,” said Prof. Nadia Bahi, MD, PhD, Pediatric Neurology at Necker-Enfants Malades University Hospital, Paris Cité University, Paris, France. “Today’s approval in the European Union is an important milestone that recognizes the significant unmet medical need in this rare disease. It provides clinicians with a new treatment option to help address the neurobehavioral symptoms of Rett syndrome and represents progress for the Rett community.”

With this approval, DAYBU is authorized to be marketed in all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. As a next step, Acadia will now begin pricing and reimbursement negotiations with relevant national authorities to potentially bring DAYBU to patients across the EU.

About Rett Syndrome

Rett syndrome is a rare, complex, neurodevelopmental disorder and occurs in approximately one of every 10,000 to 15,000 female births worldwide.^1-3 A child with Rett syndrome generally exhibits an early period of apparently normal development until six to 18 months, when many of their skills seem to slow down or stagnate. This is typically followed by a regression phase when the child loses acquired communication skills and purposeful hand use. The child may then experience a plateau period in which they could show mild recovery in cognitive interests, but body movements remain severely diminished. As they age, those individuals living with Rett may continue to experience a stage of motor deterioration, which can last the rest of the patient’s life.² Rett syndrome is typically caused by a genetic mutation on the MECP2 gene.⁴ In preclinical studies, deficiency in MeCP2 function is thought to lead to impairment in synaptic communication and brain plasticity, and the deficits in synaptic function may be associated with Rett manifestations.^4-6

Symptoms of Rett syndrome may also include development of hand stereotypies, such as hand wringing and clapping, and gait abnormalities.⁷ Most individuals living with Rett syndrome typically live into adulthood and require intense round-the-clock care.^1,8 Rett syndrome is associated with a substantial physical, psychological, social, and economic burden, significantly affecting the quality of life of both patients and their caregivers.^9-11

About DAYBU^® (trofinetide)

In Rett syndrome, levels of insulin-like growth factor 1 (IGF-1) in the brain are lower than normal, which is thought to affect nerve function. IGF-1 is a hormone that is important for the normal development and functioning of the nervous system. The active substance in DAYBU (trofinetide), is made up of a molecule derived from IGF-1.

Trofinetide is approved for use under the name DAYBUE^® and DAYBUE^®STIX in the United States and under the name DAYBUE^® in Canada and DAYBU^® in the European Union.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “potential,” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the importance of DAYBU as a treatment for neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, the anticipated benefits of DAYBU to patients, caregivers, healthcare providers, and the Rett community, the clinical benefit of DAYBU, the ability of patients to gain access to DAYBU, and our expectations regarding the future occurrence of pricing and reimbursement negotiations, including our ability to timely gain pricing and reimbursement of DAYBU^® in EU member states, Iceland, Liechtenstein, and Norway. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the inherent uncertainty regarding the pricing and reimbursement negotiations; our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; our ability to obtain necessary regulatory approvals to commercialize our products and product candidates; if and when approved, market acceptance of our products and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our quarterly report on Form 10-Q for the period ended June 30, 2026, filed on August 5, 2026, as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.

References

¹ Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatrics Open. 2020;4:e000717.

² Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 2018; 8:170216.

³ May DM, Neul JL, Satija A, et al. Real-world clinical management of individuals with Rett syndrome: a physician survey. J Med Econ. 2023;26(1):1570-1580.

⁴ Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999; 23(2):185-188.

⁵ Fukuda T, Itoh M, Ichikawa T, et al. Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J Neuropathol Exp Neurol. 2005; 64(6):537-544.

⁶ Asaka Y, Jugloff DG, Zhang L, et al. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis. 2006; 21(1):217-227.

⁷ Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010; 68(6):944-950.

⁸ Tarquinio DO, Hou W, Neul JL, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol. 2015; 53(5):402-411.

⁹ Prange EO, Beisang A, Pehlivan D, et al. Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. Annals of the Child Neurology Society. 2026; 38–51.

¹⁰ Kaufmann WE, Percy AK, Neul JL, et al. Burden of illness in Rett syndrome: initial evaluation of a disorder-specific caregiver survey. Orphanet J Rare Dis. 2024;19(1):296.

¹¹ Gold WA, Percy AK, Neul JL, et al. Rett syndrome. Nat Rev Dis Primers. 2024;10(1):84.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260824899136/en/

Investor Contact:

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

[email protected]

Acadia Pharmaceuticals Inc.

Jessica Tieszen

(858) 261-2950

[email protected]

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

[email protected]

KEYWORDS: California Europe United States North America

INDUSTRY KEYWORDS: Biotechnology General Health Neurology Health Pharmaceutical

MEDIA:

Logo

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

• Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1)

• Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo

• Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World

 

OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda’s laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible.

“Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientific innovation can create new possibilities for patients and drive future growth for Takeda”

NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of daytime and nighttime symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disrupted nighttime sleep, sleep paralysis, hallucinations and cognitive symptoms. The persistent, 24-nature of the disease can severely impact many aspects of a person’s life, including work, education and social interactions. Despite the substantial disease impact, limited awareness and the complexity of symptoms can contribute to misdiagnoses and an average diagnostic delay of more than 10 years.

“NT1 is a condition that can have a significant impact on patients’ lives around the clock. Historically, treatment has primarily focused on managing individual symptoms. In recent years, advances in our understanding of the underlying pathophysiology of narcolepsy have led to the development of new therapeutic approaches,” said Yuichi Inoue, professor, Department of Somnology, Tokyo Medical University. “I look forward to seeing a broader range of treatment options become available, helping physicians tailor treatment to the needs of each individual patient.”

The approval is based on a comprehensive clinical program including the global Phase 3 FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) studies that showed oveporexton offers statistically significant improvements across the full range of NT1 symptoms assessed. These included improvements in excessive daytime sleepiness, cataplexy and other secondary measures evaluated in the studies. Oveporexton was generally well-tolerated with a safety profile consistent across clinical studies to date. The most common adverse events were trouble sleeping (insomnia), urinary urgency, urinary frequency and excessive saliva. Learn more about the Phase 3 data results here.

“We credit our scientists in Japan who worked tirelessly to successfully discover a way to target the underlying orexin deficiency associated with narcolepsy type 1, a scientific feat that had never been achieved before,” said Asuka Miyabashira, president, Japan Pharma Business Unit at Takeda. “It’s exciting for a biopharmaceutical company to discover, develop and commercialize an asset internally, and we are proud to have worked with our colleagues, healthcare providers and patient community to bring this new class of treatment to adults living with narcolepsy type 1 in Japan.”

The MHLW approval marks the third approval of ORZEYFUL around the world. ORZEYFUL is also approved for the treatment of NT1 in China as well as the United States (U.S.) where the controlled substance classification for ORZEYFUL is currently under review by the U.S. Drug Enforcement Administration (DEA).

About ORZEYFUL (Oveporexton)

ORZEYFUL (oveporexton) is an oral orexin receptor 2 (OX2R) agonist, which selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency associated with narcolepsy type 1 (NT1). By activating OX2Rs, ORZEYFUL promotes wakefulness and reduces abnormal rapid eye movement (REM)-sleep like phenomena, including cataplexy (sudden and temporary loss of muscle tone), to address a range of daytime and nighttime symptoms as evaluated in clinical studies and consistent with the approved label.

About Takeda’s Orexin Franchise

Takeda is the leader in orexin science with a tailored portfolio of investigational orexin agonists in pre-clinical and clinical stages for multiple-sleep wake disorders and other indications where orexin plays a role including respiration, mood and metabolism. Oveporexton is the lead orexin receptor 2 (OX2R) agonist in Takeda’s orexin franchise and has been approved by regulatory bodies in China for the treatment of narcolepsy type 1 (NT1) in adolescents aged 16 and older and adults as well as in the United States and Japan for adults with NT1. The company is also investigating other oral orexin agonists, including TAK-360 for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), as well as TAK-495.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

ORZEYFUL (oveporexton) Product Overview in Japan

Product Name:

Orzeyful Tablet 0.5mg, 1mg, 2mg

Generic Name:

Oveporexton

Indications and Effects:

Narcolepsy Type 1

Dosage and administration:

The usual adult dosage of Oveporexton is 1mg administered orally two times daily. The first dose should be taken upon awakening and the second dose 3 to 5 hours later. The dose may be increased to 2 mg oral administration two times daily only when it is well tolerated and sufficient efficacy is not observed.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260818063761/en/

Investor Relations

Christopher O’Reilly

[email protected]

Media Relations

Tsuyoshi Tada (Tokyo)

[email protected]

Rachel Wallace (Boston)

[email protected]

KEYWORDS: Massachusetts United States Japan North America Asia Pacific

INDUSTRY KEYWORDS: Biotechnology FDA Health Pharmaceutical Clinical Trials

MEDIA:

Logo

Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Signs New FF Par Agreement with a Leading U.S. Robotics Distributor and Provides Details on FF EAI Robotics “Built in USA” Business Partner Conference on August 26

• FF will host Part One of the FF EAI Robotics “Built in USA” Upstream & Downstream Business Partner Conference on Aug. 26—the “Four-Core Full-Stack AI” Ecosystem Downstream Partner Session and the EAI Education Ecosystem Milestone Showcase & Nationwide Expansion Session will take place at FF’s headquarters in LA.

• FF recently signed an FF Par agreement with one of the leading robotics distributors in the U.S., with coverage across all 50 states. The group has officially become a Tier 1 distributor and robotics ecosystem partner of FF Robotics, more details to come later this week.

• FFAI recently received an upgrade to a “Buy” rating from Zacks, a well-known U.S. investment research and ratings firm, placing FF’s stock among the top 20% of the stocks it covers. According to Zacks, the consensus earnings estimate for FFAI has risen by 19.9% over the past three months.

LOS ANGELES–(BUSINESS WIRE)–
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today shared a weekly business update from YT Jia, Founder and Global CEO of FF.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823443458/en/

“Hello everyone, welcome back! Let me start Weekly Report 69 with a major milestone in FF’s Q3 “Four-Core Full-Stack AI” Robotics Practical Deployment Campaign.

Last week, FF signed an FF Par agreement with one of the leading robotics distributors in the U.S., with coverage across all 50 states. The group has officially become a Tier 1 distributor and robotics ecosystem partner of FF Robotics. We will share further details of this partnership at our August 26 Business Partner Conference. Why is this milestone so important? There are three reasons:

First, we expect it to significantly accelerate the expansion of our FF Par network across all 50 states. It will also help us bring successful use cases from our four industry ecosystems to more states.

Second, we expect it to provide stronger support for the rapid ramp-up of robot sales.

Third, it validates the strength of our products and technology and our ability to drive sales—what we call Product Power, Technology Power, and Sales Power—across our Six-Series Full-Form FF EAI Robot World under the “Four-Core Full-Stack AI” Ecosystem Strategy. It also demonstrates our strong appeal to the U.S. robotics industry, especially among distribution partners.

Next, let me preview our August 26 “Built in USA” Business Partner Conference. On August 26, we will host Part One of the FF EAI Robotics “Built in USA” Upstream & Downstream Business Partner Conference—the “Four-Core Full-Stack AI” Ecosystem Downstream Partner Session and the EAI Education Ecosystem Milestone Showcase & Nationwide Expansion Session—at our Los Angeles headquarters. The event will have seven key highlights:

1. A briefing on the FCC’s new policies and the launch of the “Built in USA” Global Industry Alliance Initiative.

2. Part One of the implementation roadmap presentation for the FF EAI Robotics “Built in USA” Acceleration Program, with Part Two scheduled for September 28.

3. A preview of two new FF EAI robotics products under the “Built in USA” program.

4. Exclusive private previews of several upcoming products from the FF EAI Robot World, including Master Mini, ahead of their September 19 launch.

5. Key milestones from the FF EAI Education Ecosystem and its nationwide expansion plan.

6. Downstream partner recruitment for the FF EAI Robotics “Built in USA” program.

7. RoboShare’s next-phase plan and business partner recruitment. RoboShare is AIxC’s robot-sharing and rental platform.

We sincerely invite our customers, channel and sales partners, educational institutions, system integrators, and ecosystem partners to join us in person, witness and participate in this initiative, and help build the EAI robotics industry ecosystem alliance based on ‘Built in USA. Benefit the World.’

On the AIxC front, last week, AIxC announced that it is fully exiting its Crypto strategy and shifting its focus to Physical AI robotics and robot sharing and rentals. We have been really encouraged by the significant attention this strategic transformation has generated across both the robotics industry and the capital markets.

As AIxC’s controlling stockholder, FF fully supports this strategic transformation. This will also enable FF and AIxC to empower each other more effectively and create stronger synergies.

RoboShare aims to become an “Uber + Turo”–style robot-sharing and operations platform. It has already completed its first paid commercial order, and its initial fleet of more than 80 EAI Devices is now in place. It has also officially launched its Ten-City Strategy, with Los Angeles as its first market.

Let’s turn to S5 — Capital. Last week, FFAI received an upgrade to a “Buy” rating from Zacks, a well-known U.S. investment research and ratings firm, placing our stock among the top 20% of the stocks it covers. According to Zacks, the consensus earnings estimate for FFAI has risen by 19.9% over the past three months. We see this as a sign that market expectations for our earnings outlook are improving.

Now, a reflection on where we need to improve. The response to AIxC’s strategic transformation far exceeded our expectations. We believe that response strongly validates our decision to focus on EAI. But it also makes us look harder at what we can do better. We still have room to improve how we prioritize our businesses, allocate resources, and set the pace of execution. Going forward, we will take a series of steps to focus first on the core EAI businesses that can reach profitability faster. This will help us unlock FF’s true value more quickly and deliver maximum value to our stockholders.

Finally, your feedback matters to us. We welcome our investors to share their comments and suggestions through our official channels, and we look forward to hearing from you and staying engaged. Thank you for your support every step of the way. See you next week!”

ABOUT FARADAY FUTURE

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a “Four-Core Full-Stack AI” ecosystem of EAI Brain, Device, Industry Productivity Solutions and Developer Platform, and Data Factory, FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future’s official website: https://www.ff.com/

FORWARD LOOKING STATEMENTS

This press release includes “forward looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “plan to,” “can,” “will,” “should,” “future,” “potential,” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding potential future legal actions against alleged illegal market manipulation or similar improper activities, and FF’s entry into the embodied AI robotics market and robotics deliveries and development, involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, that may affect actual results or outcomes include, among others: the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations, which it currently lacks; the availability of sufficient share capital to meet its current obligations and execute on its strategy; the willingness of convertible debt investors to fund the Company; demand for the Company’s robotics products; the ability of B2B preorder companies to locate customers to purchase our robotics products, on which their nonbinding preorders substantially depend; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; the ability of the Company to build an EAI education ecosystem that serves both the B2C consumer market and the B2B institutional education market; the acceptance by teachers and students of the Company’s robotics products in the education market; the ability of the Company to expand into additional markets for its robotics products; the Company’s reliance on a single OEM for most of its robotics products; the Company’s ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for imported products, particularly from China; demand from automobile dealers for robotics products; the Company’s ability to homologate FX vehicles for sale; the Company’s ability to secure the necessary funding to execute on the FX strategy, which is substantial; the Company’s ability to secure an occupancy certificate covering all of its Hanford facility; the Company’s ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of substantial losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company’s estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company’s vehicles; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company’s vehicles; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company’s operations in China; the success of the Company’s remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company’s ability to develop and protect its technologies; the Company’s ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company’s stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 14, 2026, and Form 10-K filed with the SEC on March 31, 2026, and other documents filed by the Company from time to time with the SEC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260823443458/en/

Investors (English): [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Professional Services Digital Cash Management/Digital Assets University Robotics Cryptocurrency Primary/Secondary Education Artificial Intelligence

MEDIA:

Photo

Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Signs New FF Par Agreement with a Leading U.S. Robotics Distributor and Provides Details on FF EAI Robotics “Built in USA” Business Partner Conference on August 26

Logo